Skip to nav Skip to content

Clinical Trial Search

302 Clinical Trials Found

Clinical Trial 20894

Acalabrutinib for Chronic Graft-versus-Host Disease
Disease Site: Unknown Sites
PI: Pidala, Joseph

Clinical Trial 21193

Disease Site: Brain and Nervous System, Brain metastasis
PI: Yu, Hsiang-Hsuan (Michael)

Clinical Trial 21459

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Disease Site: Colon
PI: Imanirad, Iman

Clinical Trial 21518

A Phase 1/1b Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation Positive Solid Tumors
Disease Site: Any Site
PI: Kim, Richard

Clinical Trial 90016

Disease Site: Other Hematopoietic
PI: Sandoval-Sus, Jose

Clinical Trial 21673

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety ofHER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-Based Therapy (FLAMINGO-01)
Disease Site: Breast
PI: Soyano Muller, Aixa

Clinical Trial 21894

Phase 1 Clinical Trial of lntravesical Adoptive Cell Therapy {ACT) with Tumor Infiltrating Lymphocytes (TIL) for Patients with BCG Exposed High Grade Non-Muscle Invasive Bladder Cancer {NMIBC)
Disease Site: Urinary Bladder
PI: Poch, Michael

Clinical Trial 20870

Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors
Disease Site: Other Female Genital, Ovary
PI: Chern, Jing-Yi

Clinical Trial 21117

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Conditioning Regimen in Subjects with Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
Disease Site: Kidney
PI: Chahoud, Jad

Clinical Trial 21158

Disease Site: Lung
PI: Gray, Jhanelle

Clinical Trial 21247

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK)-Inhibitor
Disease Site: Myeloid and Monocytic Leukemia
PI: Komrokji, Rami

Clinical Trial 20897

Phase 1 Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)
Disease Site: Breast
PI: Costa, Ricardo